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Abstract 
 
Purpose: To assess the stability of visual and refractive outcomes that was compared between 
three and 12 months after MyoRing implantation in moderate and severe keratoconus 
Methods: This study included 54 eyes of 50 patients (27 males and 23 females) with stage II and III 
keratoconus who underwent MyoRing (Dioptex GmbH) implantation. Clinical outcomes including 
uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest 
refraction, spherical equivalent (SE) and mean keratometry (k)- readings were compared 
preoperatively and postoperatively (follow-up times were at 1, 3, 6 and 12 months postoperation). 
Results: The mean age was 28.48±6.3. The mean UDVA (logMAR) and the mean CDVA (logMAR) 
improved significantly from 1.20±0.24 to 0.20±0.09 and from 0.58±0.22 to 0.14±0.06, respectively 
(p<0.001). Both SE and the maximum keratometry (k)-reading decreased significantly by six 
diopters (p<0.001). There was no significant difference in visual and refractive outcomes between 
three and 12 months postoperatively. Twelve months after MyoRig implantation the predictability 
was 47 eyes (87%) within ±1.00 D and 31 eyes (57%) within ±0.50 D of emmetropia.  
Conclusion: MyoRing implantation in keratoconic patients improves SE, UDVA and CDVA 
significantly. Additionally, the improvement in UDVA was remarkable (approximately 10 lines). The 
procedure was safe and effective in treatment of patients with moderate and severe keratoconus. 
The visual and refractive outcomes remained stable between three and 12 months postoperatively.  
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Introduction 
Keratoconus is a progressive, non-
inflammatory ectatic disorder which leads to 
corneal thinning and gradual biomechanical 
instability of the cornea. The corneal thinning 
induces irregular astigmatism and progressive 
myopia. This condition decreases the visual 
quality in keratoconic patients.1,2 
Keratoconus appears to be a multifactorial 
disease caused by a combination of several 
genes abnormalities, environmental factors 
(including atopy, eye rubbing, contact lens 
use, oxidative damage) and ultrastractural 
alteration of the collagen matrix. However, the 
exact etiology of this disorder remains to be 
unknown.3 
To treat keratoconic patients, non-surgical 
methods including spectacles and hard 
contact lenses are used. However, surgical 
procedures should be applied if these optical 
tools could not restore the vision or patients 
could not tolerate the hard contact lens. 
The main surgical therapeutic option for 
more advanced cases is lamellar or 
penetrating keratoplasty.4,5 In spite of its 
acceptable results, collagen cross-linking 
(CXL) and intracorneal ring segments (ICRS) 
have provided an alternative to manage 
keratoconus as less invasive procedures.6-13 
Also, the use of full-ring implants has been 
proposed as a potential solution for the 
treatment of corneal irregularity in keratoconic 
patients.14-16 MyoRing is a full-ring intracorneal 
implant (DIOPTEX GmbH) which be inserted 
into the cornea by means of a new surgical 
technique called “Corneal Intrastromal 
Implantation System” (CISIS). 
Previous studies on MyorRing implantation 
have reported that MyoRing is an effective 
and safe method to correct high myopia and 
keratoconous.14-19 However, to our knowledge, 
few studies have investigated the stability of 
visual and refractive outcomes after MyoRing 
implantation during 12 month follow-up. To 
address this issue, we conducted this 
retrospective study. 
 
Methods 
Study population and assessment 
This retrospective cohort study included 54 
keratoconic eyes of 50 patients who 
underwent MyoRing intra-corneal implantation 
(created by the pocketMaker microkeratome; 
Dioptex GmbH) at Bina Eye Hospital, Tehran, 
Iran, between November 2010 and July 2011. 
All participants were selected from the pool of 
outpatients with keratoconus. 
Keratoconus diagnosis was based on  
slit-lamp examination and corneal topography. 
The characteristics of keratoconus were 
observed in all patients: corneal topography 
revealing an asymmetric bowtie pattern with 
or without skewed axes and at least one 
keratoconus sign on slit-lamp examination, 
such as stromal thinning, conical protrusion of 
the cornea at the apex, Vogt Striae or 
Fleischer ring. The severity of keratoconus 
was graded according to the Amsler–
Krumiech classification.20 
MyoRing is a flexible, full-ring intracorneal 
implant (Dioptex GmbH) which is available in 
a diameter range of 5 to 6 mm and thickness 
range of 200 to 400 μm in 20 μm increments. 
The width of the ring body is 0.50 mm. The 
implant is made of polymethyl metacrylate 
(PMMA). The anterior surface is convex and 
the posterior surface concave, with a radius of 
curvature of 8.00 mm.14 
The appropriate MyoRing dimensions 
(diameter and thickness) were selected 
according to the MyoRing nomogram that was 
derived from theoretical calculation based on 
a biomechanical corneal model which was 
developed by Albert Daxer on the basis of 
experimental data.21-23 This nomogram takes 
into account the corneal thickness at its 
thinnest point and the mean central 
keratometry (K) -reading.15 
In all eyes, ophthalmic examinations 
included uncorrected distance visual acuity 
(UDVA), manifest refraction with corrected 
distance visual acuity (CDVA), corneal 
topography (Orbscan II, Baush & Lomb), 
Goldmann applanation tonometry, slit-lamp 
biomicroscopy and fundus examination. Lines 
of improvement in acuity were calculated in 
logarithmic scales according to logMAR 
notation. Patients were followed at 1, 3, 6 and 
12 months after surgery. 
Inclusion criteria were age older than 19 
years, contact lens intolerance, clear central 
corneas, proof of keratoconus evolution and 
minimal corneal thickness >350 μm. Exclusion 
criteria were patients with stage I and IV 
keratoconus, hydrops, corneal opacity, 
corneal dystrophy, herpetic keratitis, previous 
ocular surgery (including CXL), pregnancy, 
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autoimmune or other systemic diseases. All 
patients were fully informed about the details 
and possible risks of the procedure. 
 
Safety, efficacy, and predictability of 
refractive correction 
The safety of the procedure was defined as 
the percentage of eyes losing more than two 
lines of Snellen CDVA. The safety index is 
equal to the ratio of mean postoperative 
CDVA to mean preoperative CDVA. The 
efficacy was defined as the percentage of the 
eyes achieving a UDVA of 20/40 or better 
postoperatively. The efficacy index is equal to 
the ratio of mean postoperative UDVA to 
mean preoperative CDVA.24,25 
The predictability of refractive correction 
was the percentage of eyes with ±1 D and 
±0.50 D of emmetropia at 12 months 
postoperatively.26 
 
Surgical technique 
All surgeries were performed by the same 
surgeon (KHJ). The system for preparing the 
tissue and inserting MyoRing into the cornea 
is called CISIS. The surgical technique is 
characterized by a two-step procedure: 
Step 1: Creation of a closed corneal pocket 
of 9 mm in diameter and 300 μm in depth by 
means of PocketMaker microkeratom. The 
equipment consists of a suction ring, a 
transparent disposable applanator which 
defines the cutting depth (A 300 μm  
applanator can be ordered from the 
company), and a micro-vibrating diamond 
blade with its tip following a circular curve of  
9 mm in diameter without passing through the 
cornea along this path.  
Step 2: MyoRing implantation into the 
pocket: using an implantation forceps in one 
dimension, the MyoRing (360º and deformable 
ring) is inserted into the corneal pocket via a 
small incision tunnel which is located in the 
temporal periphery of the cornea. Once 
placed into the pocket, the MyoRing inflates to 
its original preoperative shape. The surgical 
technique is described in more detail 
elsewhere.17 
The surgery was performed under topical 
anesthesia. Postoperatively, patients were 
prescribed to use chloramphenicol and 
bethamethasone drops four times daily. 
Chloramphenicol was interrupted one week 
after surgery whereas bethamethasone was 
tapered off during 4-6 weeks. 
 
Statistical analysis 
Statistical analysis was performed using 
SPSS version 16 for Windows (version 16; 
SPSS Inc., Chicago, IL, USA). All visual acuity 
measurements were converted from Snellen 
notation to logMAR. The normality of 
distribution was checked for all variables. 
Continuous variables are expressed as 
mean±SD [range].  
Differences between pre and postoperative 
refractive and visual outcomes were tested 
using paired t-test. The results were 
compared between preoperative and 
postoperative examination. In addition, the 
results of 3rd and 12th months of postoperative 
follow-up were compared. The threshold of 
statistical significance was a p value less than 
0.05. 
 
Results 
This study evaluated 54 eyes of 50 patients 
(27 males and 23 female). The mean age was 
28.48±6.3 years old [range 20 to 45]. There 
were 40 eyes (74.1%) with stage II and 14 
eyes (25.9%) with stage III keratoconus. No 
significant difference was noted between sex 
groups (p=0.571).  
The clinical outcome of MyoRing 
implantation was compared at 3 and 12 
months postoperatively which was not 
observed significant difference between 
identical values. Table 1 shows the visual and 
refractive outcomes during 12 months  
follow-up. 
 
Visual outcome, efficacy and safety 
The mean UDVA (logMAR) was 1.20±0.2 
[range 0.50 to 1.30] preoperatively and 
0.3±0.1 [range 0.10 to 0.50] and 0.2±0.1 
[range 0.00 to 0.40] at 3rd and 12th months, 
respectively (both p<0.001). There was a 
statistically improvement in mean UDVA from 
three months to 12 months postoperatively 
(p=0.016; Figure 1  demonstrates the changes 
in UDVA during the 12 months follow-up). 
Preoperatively, 50 out of 54 eyes (92%) 
had an uncorrected visual acuity (UCVA) of 
20/200 or worse, whereas 53 eyes (97%) had a 
UCVA of 20/40 or better 12 months after 
surgery.  
D
ow
nl
oa
de
d 
fro
m
 ir
jo.
org
 at
 21
:19
 IR
ST
 on
 Tu
es
da
y J
an
ua
ry 
17
th 
20
17
Mojaled Nobari et al  •  Intrastromal Corneal Ring (MyoRing) in Keratoconic Eyes 
 
 139 
At 12 months (N=54 eyes) the UDVA was 20/50 
in one eye, 20/40 in 17 eyes, 
20/32 in 26 eyes, 
20/25 in 7 eyes and 
20/20 in 4 eyes. The 
improvement in mean UDVA was 
approximately 10 lines after 12 months. The 
efficacy index was 1.96 at 12 months. 
The mean CDVA (logMAR) in all operated 
eyes improved significantly from 0.6±0.2 
[range 0.30 to 1.20] preoperatively to 0.2±0.1 
[range 0.00 to 0.40] and 0.1±0.1 [range 0.00 
to 0.20] at 3 and 12 months postoperatively 
(both p<0.001).  
The mean CDVA improved statistically at 
12 months when compared to three months 
postoperatively (p=0.017). At 12 months, the 
CDVA was 20/32 in 32 eyes, 
20/25 in 18 eyes 
and 20/20 in four eyes. Also, 12 months after 
surgery, the improvement in mean CDVA was 
approximately four lines. The procedure was 
safe because no patient lost more than two 
lines of snellen CDVA. The safety index was 
2.5 at 12 months. 
 
Refractive and keratometry outcomes 
The mean sphere of manifest refraction 
improved significantly from -4.6±3.7 D (range,  
-12.00 to +3.00 D) preoperatively to 0.7±1.0 D 
(range, -3.50 to +2.00 D) and 0.7±1.0 D 
(range, -3.50 to +2.50 D) at 3 and 12 months 
postoperatively, respectively (both p<0.001).  
The mean preoperative cylinder 
significantly decreased from -5.2±1.0 D 
(range, -3.00 to -7.00 D) to -1.8±0.7 D (-1.00 
to -3.50 D) and -1.5±0.7 D (range, -0.50 to  
-3.50 D) at 3 and 12 months postoperatively, 
respectively (both p<0.001).  
The mean preoperative SE was -6.1±3.5 D 
(range, -14.00 to +1.50 D), which improved to 
-0.2±0.7 (range, -4.50 to +1.50 D) and  
-0.1±0.7 (range, -4.00 to +1.00 D) at 3 and 12 
month postoperatively, respectively (both 
p<0.001). We found that there was not 
statistically significant difference in sphere 
(p=0.267), cylinder (p=0.471) and SE 
(p=0.525) between three and 12 months 
postoperatively. Figure 2 shows the changes 
in SE during the 12 months follow-up. 
In terms of refractive predictability, 47 eyes 
(87%) were within ±1.00 D and 31 eyes 
(57.4%) were within ±0.50 D of emmetropia.  
The steep keratometric value (kmax) 
decreased significantly from 52.97±3.54 D 
(range, 48 to 60 D) preoperatively to 
47.10±2.37 at 12 months postoperatively 
(range, 43.50 to 51 D) (p<0.001). Table 2 
summarizes mean keratometric values 
preoperatively and 12 months postoperatively. 
The mean central corneal thickness (CCT) 
was 439.62±35.42 preoperatively and 
436.21±28.43 at 12 months postoperatively 
with no statistically significant change 
(p=0.22). 
The patients were divided in two groups 
based on the MyoRing diameter (group 1 
included 30 eyes with 5 mm diameter and 
group 2 included 24 eyes with 6 mm diameter. 
No significant difference was noted between 
identical values of the two groups. The mean 
UDVA was 0.2±0.09 in group 1 and 0.22±0.89 
in group 2, which was not statistically 
significant difference between two groups 
(p=0.71). The mean CDVA was 0.15±0.06 in 
group 1 and 0.16±0.07 in group 2 with no 
statistically significant difference (p=0.56). 
Also no significant difference was noted in 
spherical equivalent (SE), sphere and cylinder 
of manifest refraction between two groups. 
The mean postoperative data are shown in 
table 3. 
 
 
Table 1. Mean preoperative and postoperative visual and refractive outcomes during one year follow-up period 
Parameters Preop 
 Postop  p value 
 
1 Month 3 Month 6 Month 1 Year  
Preop vs 3 
Month 
3 Month vs 
1 Year 
Preop vs 
1 Year 
UDVA (logMAR) 1.2±0.2  0.3±0.2 0.3±0.1 0.2±0.1 0.2±0.1  <0.001 0.016 <0.001 
CDVA (logMAR) 0.6±0.2  0.2±0.1 0.2±0.1 0.2±0.1 0.1±0.1  <0.001 0.017 <0.001 
Sphere (D) -4.6±3.7  0.8±1.1 0.7±1.0 0.6±1.0 0.6±1.0  <0.001 0.267 <0.001 
Cylinder (D) -5.2±1.0  -2.0±1.1 -1.8±0.7 -1.5±1.0 -1.5±0.7  <0.001 0.471 <0.001 
SE (D) -6.1±3.5  -0.2±1.0 -0.2±0.7 -0.2±0.9 -0.1±0.9  <0.001 0.525 <0.001 
 
UDVA: Uncorrected distance visual acuity, CDVA: Corrected distance visual acuity, SE: Spherical equivalent, D: Diopters,  
Postop: Postoperative, Preop: Preoperative 
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Table 2. Mean of the keratometric (K) values before and 12 months postoperative as well as 
the amount of reduction 
 Preoperative Postoperative Pre-Post
ǂ
 p value 
Kmax (D) 52.97±3.54 47.10±2.37 5.87 <0.001 
Kmin (D) 47.49±3.04 44.95±2.52 2.54 <0.001 
Kaverage (D) 50.19±3.10 45.75±2.37 4.44 <0.001 
 
D: Diopters, Kmax: Maximum K value in diopters, Kmin: Minimum K value in diopters, 
Kmean: Average K value in diopters, ǂ: Difference between preop and postop K 
 
 
Table 3. Postoperative data based on the MyoRing diameter (5 mm and 6 mm) 
Parameter Ring diameter Mean±SD p-value 
SE (D) 
5 
6 
0.04±1.00 
0.24±0.69 
0.66 
UDVA (logMAR) 
5 
6 
0.20±0.09 
0.22±0.89 
0.79 
CDVA (logMAR) 
5 
6 
0.15±0.06 
0.16±0.07 
0.56 
Sphere (D) 
5 
6 
0.77±1.09 
0.53±0.75 
0.84 
Cylinder (D) 
5 
6 
-1.47±0.64 
-1.56±0.61 
0.94 
 
SE: Spherical equivalent, UDVA: Uncorrected distance visual acuity, CDVA: Corrected 
distance visual acuity, D: Diopeter 
 
 
  
Figure 1. Changes in uncorrected visual acuity 
during the 12 months follow-up 
Figure 2. Changes in spherical equivalent during 
the 12 months follow-up 
 
 
Discussion 
The MyoRing intracorneal implantation has 
been used to manage high myopia and 
keratoconus. The technique to place MyoRing 
in the pocket by means of a mechanical 
dissector is called CISIS. The mechanism of 
action for CISIS is volume added in the 
periphery which leads to a new biomechanical 
equilibrium of the cornea, thereby flattening its 
center.15,17 
The results of this study showed an overall 
10 lines increase in the mean UDVA at 12 
months postoperatively. Additionally, it 
revealed that the results of visual and 
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refractive outcomes between 3rd and 12th 
months follow-up were stable. 
According to previous studies of MyoRing 
implantation, CISIS appears to be safe and 
effective in decreasing myopia, corneal 
steepness and decentration of the corneal 
apex.14-18 Our results in accordance with those 
studies demonstrated that CISIS was an 
effective procedure for keratoconus 
correction. 
In contrast to Jabarvand et al19 who 
reported that males had better outcomes in 
comparison to females, no significant 
difference was noted between sex groups in 
our study. 
In the current study, there was a significant 
improvement in the mean UDVA from 20/320 to 
20/32 (approximately 10 lines) 12 months after 
surgery. Furthermore, CDVA improved from 
20/80 to 
20/32 (approximately four lines). These 
levels of improvement in UDVA and CDVA are 
consistent with the results of a study by Daxer 
et al.16 On the other hand, in contrast to other 
MyoRing studies and previous reports of 
ICRS, our results showed a greater 
improvement in mean UDVA.7-14,18,19 Alio et al 
reported that in 12 keratoconic eyes with 
MyoRing implantation, the mean UDVA 
increased from 1.36 logMAR to 0.61 
logMAR.18 Jabarvand et al showed a mean 
change of six lines in a sample of 95 
keratoconic eyes.19 Mahmood et al reported 
that the mean gain in UDVA was seven lines 
in six keratoconic eyes.14 
In a study by Shabayek et al, the mean 
change of UDVA was approximately six lines 
in 21 keratoconic eyes implanted with 
KeraRing ICRS.10 Colin et al reported that the 
mean improvement in mean UDVA was 
almost five lines after Intacs implantation in 
100 keratoconic eyes.9 
In this study, following MayoRing 
implantation, the mean spherical and 
cylindrical components of manifest refraction 
decreased by 5.30 and 3.70 D, respectively. 
In agreement with other MyoRing studies, our 
results showed a greater improvement in 
sphere in comparison with the cylindrical 
component of the manifest refraction. This 
finding could be due to the specific circular 
shape of MyoRing. Consequently, it has a 
greater effect on the corneal power than 
ICRS, which impacts strongly the spherical 
component of refraction. It has been proven 
that intrastromal corneal ring segments act by 
an arc-shortening effect on the corneal 
lamellae and flatten the cornea.27 MyoRing as 
a result of its continues design has a greater 
flattening effect and this is probably the 
reason why the UDVA improvement after 
MyoRing implantation is so impressive even 
though the improvement in the cylinder is less 
than sphere. 
Previous MyoRing studies have assessed 
the efficacy and safety of MyoRing 
implantation for myopia and keratoconus 
correction.14,16,18 The safety and efficacy index 
in this study confirmed the safety and 
efficiency of this procedure. 
 Although there was a statistically 
significant difference in both UDVA and CDVA 
between three and 12 months after surgery, 
this difference was approximately equal to one 
line which is not clinically important. 
In this study, there were 5.20, 3.50 and 
6.00 D reduction in the mean sphere, manifest 
cylinder, and SE three months after surgery 
respectively. Also, 12 months after surgery the 
mean sphere, manifest cylinder and SE 
reduced by 5.30, 3.30 and 6.00 D, 
respectively. These results are in accordance 
with the findings of other MyoRing studies 
although the reduction in refractive outcomes 
in this study were more than those reported in 
previous studies on ICRS; for example, in a 
study by Shabayek et al, the mean decrease 
in sphere, cylinder, and SE was 0.96, 2,67 
and 2.23 D after KeraRing implantation, 
respectively.10 
In a study by Colin et al, the cylinder and 
SE decreased by 1.31 and 3.13 D following 
Intacs implantation, respectively.9 
Taking into account the results of this 
study, it seems that both visual and refractive 
outcomes were stabilized in the 3rd months 
after surgery. This result is possibly due to 
biomechanical changes after MyoRing 
implantation. It has been demonstrated that 
addition of the extra material at the corneal 
mid-periphery induces the displacement of the 
local anterior surface forward to this area and 
flattening of the central portion of the anterior 
cornea caused by the morphologic structure of 
the corneal lamellae.21 
Regarding corneal topography, the 
maximum keratometry reading (Kmax) 
decreased approximately by 6.00 D. This 
flattening was consistent with the results of 
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the study by Daxer et al16 whereas Alio et al 
and Jabarvand et al reported a reduction of 8 
and 9 D, respectively.18,19 
According to the MyoRing nomogram, 
more advanced keratoconus cases need to be 
treated with a thicker implant and reduced 
diameter. In our sample, a significant number 
of eyes had grade II (moderate) keratoconus 
whereas most of the eyes had grade III and IV 
keratoconus in studies performed by Alio  
et al18 and Jabarvand et al.19 Therefore, we 
suppose that the greater flattening effect 
observed in these studies is probably due to 
the use of thicker implants and reduced 
diameter which are factors proven to be 
related to a more significant flattening.21 
Alio et al18 reported significant thickening of 
the CCT after MyoRing implantation while 
there were no significant changes 
postoperatively in our study with a larger 
sample size, which consistent with the results 
of a study by Jabarvand et al.19 
Although there was no complication in any 
case during the surgery or follow-up, one 
limitation of this study was the  
non-homogeneous number of patients in each 
stage of keratoconus; thus, it would be 
interesting to carry out further long term, 
prospective, comparative studies to assess 
this procedure in different stages of 
keratoconus. 
 
Conclusion 
In conclusion, MyoRing leads to an impressive 
reduction of spherical and cylinder 
components of manifest refraction by 
flattening the central cornea. MyoRing 
implantation was a safe and effective 
procedure for the management of moderate 
and severe keratoconus. 
CISIS significantly improved both UDVA 
and CDVA although the improvement of 
UDVA was more impressive. Moreover, the 
improvement in UDVA after MyoRing 
implantation was more than those reported 
after ICRS implantation in keratoconic 
patients. However, additional comparative 
studies should be performed to compare 
MyoRing and ICRS.  
The stability of visual and refractive 
outcomes between three and 12 months 
postoperatively indicates that MyoRing could 
affect keratoconus progression; however, 
further prospective, randomized studies are 
recommended to establish the role of 
MyoRing in controlling the progression of 
keratoconus. 
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